$BIOA's BGE-102 showed ≥85% median hsCRP reductions in Phase 1; strong IL-6, fibrinogen drops; well-tolerated. Phase 2 trials planned for mid-2026.
www.biopharmcatalyst.com/news/2026/sp...
$TOVX to present more VIRAGE Phase 2b data at AACR 2026, showing VCN-01 combo benefits in metastatic pancreatic cancer, supporting plans for Phase 3 trial.
www.biopharmcatalyst.com/news/2026/th...
BioPharmCatalyst Weekly Watchlist: Top biotech catalyst events for early 2026. Key tickers: CNTB, CNTX, CRBP, ORKA, TYRA, TRDA, GSK, QTTB. Get updates in our biotech newsletter! www.biopharmcatalyst.com/news/2026/bi...
$ALGS inks $25M upfront, up to $420M milestones HBV China deal with Amoytop, keeps ex-China rights; extends cash runway into Q4 2026.
www.biopharmcatalyst.com/news/2026/al...
$IMMP: Eftilagimod alfa gets FDA Orphan Drug status for soft tissue sarcoma after positive Phase II results. COO Deanne Diem Miller files Form 3 for initial ownership.
www.biopharmcatalyst.com/news/2026/he...
$AVNS to be acquired by American Industrial Partners in an all-cash deal; valuation undisclosed.
www.biopharmcatalyst.com/news/2026/av...
$REPL drops premarket after FDA rejects its skin cancer therapy again; J.P. Morgan and Piper Sandler downgrade amid approval uncertainty.
www.biopharmcatalyst.com/news/2026/vi...
This week’s biotech watchlist: Key PDUFA dates for CNTB, CNTX, CRBP, ORKA, TYRA, TRDA, GSK, QTTB, and more. Stay updated on top stock catalysts! www.biopharmcatalyst.com/news/2026/bi...
$SLP Q2 revenue up 8% to $24.3M, gross margin 66%, EPS $0.22, showing stronger profitability and leverage. $SLP $MGNX $TLX $TLSI $ONCO $MIST $DRMA $PSTV $GLMD $TELO
www.biopharmcatalyst.com/news/2026/si...
$GLMD unveils brain-penetrant Aramchol via lipid nanoparticles, targeting CNS diseases like Parkinson’s through SCD1 inhibition.
www.biopharmcatalyst.com/news/2026/ga...
$ELAB maxed out its $20M equity line, now focusing on margin growth, M&A in aerospace/defense, and advancing EL-22 to Phase 2 IND. $ELAB #premarket
www.biopharmcatalyst.com/news/2026/pm...
$KPRX secured $5M from Perceptive & ADAR1, plus up to $19M via warrants, to fund pipeline and business ops.
www.biopharmcatalyst.com/news/2026/si...
$SLNO to be acquired by $NBIX for $53/share ($2.9B). Deal adds VYKAT XR, first FDA-approved PWS hyperphagia drug. $SLNO + others: $ANVS $ADTX $HOTH $SCNI $STXS $CANF $PRQR $VRAX $COCP.
www.biopharmcatalyst.com/news/2026/so...
BioPharmCatalyst Watchlist: Top biotech stocks to watch—CNTB, CNTX, CRBP & more. Get daily insights & catalysts. Full article: www.biopharmcatalyst.com/news/2026/ www.biopharmcatalyst.com/news/2026/bi...
$INO proposes equity offering with Series A/B warrants (plus 15% greenshoe), likely causing near-term dilution to fund operations.
www.biopharmcatalyst.com/news/2026/in...
$CYCN merges with Korsana, will trade as $KRSA. $380M financing secured, funding ops into 2029. $FBLG $BCAB $KALA $ORIC $NCEL $ELAB $AAPG $IOBT $VRAX pre-market movers.
www.biopharmcatalyst.com/news/2026/cy...
$IOBT filed for Chapter 7 bankruptcy on March 31, 2026, ceased operations, and initiated liquidation proceedings in the U.S. Bankruptcy Court.
$APLS $IOBT $PEPG $CNTA $PSTV $CTXR $CGTX $PASG $ITRM $FBLG
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2026/ap...
$LLY to acquire $CNTA for up to $47/share, boosting its neuroscience pipeline with OX2R agonist cleminorexton. $CNTA, $PSTV, $APLS, $SRRK among pre-market movers.
www.biopharmcatalyst.com/news/2026/el...
$PEPG reported Phase 2 FREEDOM2-DM1 data from the 5 mg/kg multiple ascending dose cohort of PGN-EDODM1 in myotonic dystrophy type 1
$ITRM $ELAB $PEPG $KZR $ICU $ARTL $CMND $CDT $FBLG $AIM
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2026/it...
$ITRM filed for liquidation after failing to raise capital or stay on Nasdaq, despite FDA approval and US launch of ORLYNVAH. Product withdrawal may happen.
www.biopharmcatalyst.com/news/2026/it...
Biotech weekly watchlist: Top Phase 3 catalysts to watch. Key tickers: NVCR, ADCT, MNMD, PTN & more. Stay updated with daily insights and news. More: bit.ly/biopharmcatalyst www.biopharmcatalyst.com/news/2026/bi...
$RCKT gets FDA nod for KRESLADI, a first gene therapy for severe LAD-I in kids; earns Rare Pediatric Disease Voucher.
www.biopharmcatalyst.com/news/2026/on...
$WVE: Phase 1 data shows -14% visceral fat, lean mass preserved after 1 dose. Advancing to Phase 2a for obesity; potential broad cardiometabolic benefits.
www.biopharmcatalyst.com/news/2026/wa...
$AVXL withdrew its EU Alzheimer's drug application after negative EMA feedback, a setback as it continues clinical trials. $BEAM $TERN $OSTX $DBVT $MAZE $ELVN $BIAF $NCNA $RENB
www.biopharmcatalyst.com/news/2026/an...
$OTLK prices 20M shares + warrants at $0.25 in $5M offering, highlighting ongoing dilutive funding needs.
www.biopharmcatalyst.com/news/2026/ka...
$APGE surges on strong Phase 2 data for zumilokibart (up to 85% EASI-75) with infrequent dosing; Phase 3 set for 2H26. $VALN $INSM $PYXS $OCGN $AVTX $MGRX $AIFF $IBO $CODX
www.biopharmcatalyst.com/news/2026/ap...
BioPharmCatalyst Weekly Watchlist: Key biotech stocks to watch, latest catalysts, & news. Get daily updates: www.biopharmcatalyst.com/news/2026/bi... www.biopharmcatalyst.com/news/2026/bi...
